Thursday, January 13, 2022

Heartless Bastards!!


 Sky-Scraper buildings

are warm at night...

With empty floors and Neon Lights

and solid doors locked tight

against helpless poor who's desperate plight 

are ignored on sight...

And outside...

Another homeless person dies

in the freezing cold of a

Winter's night...

---------------------------------------

N.J.R.

Wednesday, January 5, 2022

 Hello Gentle People:

 Apparently the Omicron variant of Sars-CoV2 is more dangerous than even the Delta variant. 

Why? Because it spreads faster and sadly it also kills people. Even Three vaccines are not enough to protect us against this vicious virus!

Once again we must do everything to block the damn thing and once again we may need another vaccine. Yes, another vaccine because the Three predecessors were all aimed at the original Covid 19 and the Omicron is a two step variation away from the original.

 The deadly Omicron variant spreads faster and even with Three vaccines, you are not protected.

A fourth vaccine and maybe more is needed. Don't let down your guard or your masks until the Hospitals finally give us the all clear signal. Do not be blasé about this virus or you may end up in a body bag. 

N.J.R

  • On 26 November 2021, the World Health Organization ( W.H.O.) designated the
  •  variant B.1.1.529 a variant of concern (VOC), on the basis of advice from WHO’s 
  • Technical Advisory Group on Virus Evolution. 
  • The variant has been given the name Omicron. 
  • Omicron variant is a highly divergent variant with a high number of mutations, including 
  • 26-32 in the spike protein, some of which are concerning and may be associated with
  •  immune escape potential and higher transmissibility.
  •  However, there are still considerable uncertainties.
  •  As of 9 December 2021, cases of human infections with this variant have been identified
  •  in 63 countries across all six WHO regions.
  •  Current understanding of the Omicron variant from recent data are likely to evolve as 
  • more data becomes available.
  • The overall threat posed by Omicron largely depends on three key questions,
  •  including: (1) how transmissible the variant is; 
  • (2) how well vaccines and prior infection protect against infection, transmission, 
  • clinical disease and death; and (3) how virulent the variant is compared to other variants.                                                      Public health advice is based on current information and will be tailored as more evidence
  •  emerges around those key questions.
  • Based on current limited evidence Omicron appears to have a growth advantage over 
  • Delta. It is spreading faster than the Delta variant in South Africa where Delta circulation 
  • was low, but also appears to spread more quickly than the Delta variant in other countries
  •  where the incidence of Delta is high, such as in the United Kingdom. 
  • Whether Omicron’s observed rapid growth rate in countries with high levels of population 
  • immunity is related to immune evasion, intrinsic increased transmissibility, 
  • or a combination of both remains uncertain. However, given the current available data,
  •  it is likely that Omicron will outpace the Delta variant where community transmission occurs.
  • There are still limited data on the clinical severity of Omicron. 
  • While preliminary findings from South Africa suggest it may be less severe than Delta,
  •  and all cases reported in the EU/EEA to date have been mild or asymptomatic, 
  • it remains unclear to what extent Omicron may be inherently less virulent.
  •  More data are needed to understand the severity profile.
  • There are limited available data, and no peer-reviewed evidence, on vaccine efficacy or
  •  effectiveness to date for Omicron. Preliminary evidence, and the considerably altered 
  • antigenic profile of the Omicron spike protein, suggests a reduction in vaccine efficacy
  •  against infection and transmission associated with Omicron. 
  • There is some preliminary evidence that the incidence of reinfection has increased 
  • in South Africa, which may be associated with humoral (antibody-mediated) immune
  •  evasion. In addition, preliminary evidence from a few studies of limited sample size 
  • have shown that sera obtained from vaccinated and previously infected individuals had 
  • lower neutralization activity (the size of the reduction ranges considerably) than with
  •  any other circulating VOCs of SARS-CoV-2 and the ancestral strain.
  • The diagnostic accuracy of routinely used PCR and antigen-based rapid diagnostic test
  •  (Ag-RDT) assays does not appear to be influenced by Omicron. 
  • Most Omicron variant sequences reported include a deletion in the S gene, causing 
  • some S gene targeting PCR assays to appear negative. 
  • Although some publicly shared sequences lack this deletion, this remains a minority of 
  • currently available sequences, and S gene target failure (SGTF) can therefore be used
  •  as a useful proxy marker of Omicron, for surveillance purposes. 
  • However, confirmation should be obtained by sequencing, as this
  •  deletion can also be found in other VOCs (e.g., Alpha and subsets of Gamma and Delta).
  • Therapeutic interventions for the management of patients with severe or critical
  •  COVID-19 associated with the Omicron variant that target host responses
  •  (such as corticosteroids, and interleukin 6 receptor blockers and prophylaxis with
  •  anticoagulation) are expected to remain effective.  
  • However, monoclonal antibodies will need to be tested individually, for their 
  • antigen binding and virus neutralization and these studies should be prioritized.
  • Tuesday, January 4, 2022

    Correct me if I am wrong but this is my THEORY FOR GRAVITY.


      What can be said about our Sun?

     1.  It is a large Hydrogen fusion reactor so hot it creates a giant ball of plasma.

     2.  Plasma is so intense it breaks apart Atoms into their component sub-atomic particles.

     3.  When Atoms split they create an explosive chain reaction which releases tremendous amounts of energy but when Atoms are fused together by pressure and heat, they become Plasma and this also releases tremendous amounts of energy.

     4.  Sub Atomic particles in the form of radiation and Photons blast out into space but much of that energy is sucked back into the Sun by gravity. The gigantic mass of the Sun creates gravity which sucks in any and all elements unlucky enough to be passing near. One of the most abundant elements in the universe is Hydrogen and that is the main fuel for the Hydrogen fusion reaction within the Sun.

    5.   The explosive force of our Sun is so strong it sends radiation and Photons millions of miles out into space. On Earth we feel the heat and we see the light from our Sun.

    6,   For every action there is a reaction and so for our Sun the force of drag of an Atom is proportional to the square of the velocity times the mass of the Sun. This force of drag is gravity.      

    7. Plasma smashing apart Atoms at tremendous speed creates a force of drag reaction. The "drag" is created when newly created sub atomic vacuum holes are quickly filled in with new Atoms. 

    8. Vacuum holes are created when Atoms are smashed by the heat and pressure of Plasma and then exploded into the Universe. We can assume that the force of drag of sub-atomic particles are also proportional to the square of their velocity multiplied by the mass of the Sun. This creates a force of drag so powerful energy drops or is sucked into it in order to replace lost Atomic particles blasted out into space. We call this force Gravity.

    9. Without mass and heat and pressure uniting Atoms or smashing them apart, there is very little gravity created.   

    10. When an element, such as Hydrogen, falls into the sun it becomes fuel for the Hydrogen fusion reaction which creates Plasma which in turn smashes more Atoms into particles. The particles leave so fast they create sub atomic vacuums that when multiplied by the mass of the sun, becomes gravity and gravity then drags in more Hydrogen Atoms which maintains the fusion reaction. 


    CONCLUSION: Heat and pressure creates fusion which in turn creates Plasma which destroys Atoms and blasts their sub- Atomic particles into space in the form of light Photons, Radiation and Heat. The quick destruction of Atoms creates sub-atomic vacuum holes and since nature abhors vacuums, the holes are quickly replaced by new Atoms. Since Hydrogen is the most abundant element in the Universe, Hydrogen falls into the Sun and fuels the Sun's Plasma reaction.

       Our Sun is a large Hydrogen fusion reactor creating a giant ball of Plasma which is so hot it breaks apart Atoms and blasts heat and light Photons into space. When sub-atomic particles are lost into space, vacuum holes are created. New Atoms quickly replace the particles lost and this replacement process times the mass of the Sun, is gravity.  


      New Atoms are mostly Hydrogen and they in turn are pulled apart by heat and pressure and their particles blasted out into space. When destroyed, Atoms leave a space much like a truck on a highway creates a vacuum turbulence. Air quickly fills the vacuum space created behind the truck. With Hydrogen fusion  high energy Plasma smashes together Hydrogen Atoms and energy is released creating tiny spaces or vacuum holes. These holes are quickly filled in with new Elements (mainly Hydrogen Atoms) falling or being sucked into the Sun and this process we know as gravity. The new Atoms then become part of the massive fusion reaction which creates heat and light for all life on Earth.   

    Author: @ Nelson Joseph Raglione 

    Sunday, December 19, 2021

    COVID-19 vaccine: What’s RNA                                      research got to do with it?        

    December 14, 2020
    Illustration of coronavirus protein binding to receptor on human cell.A coronavirus uses a protein on its membrane—shown here in red in a molecular model—to bind to a receptor—                                                                                                   shown in blue—on a human cell to enter the cell. Once inside, the virus uses the cells' machinery to make more                                                                             copies of itself. (Juan Gaertner / Science Source)               
    Rochester research into RNA structure and             function provides key information for developing coronavirus treatments.

    The US Food and Drug Administration recently approved emergency use                                                                authorization for a COVID-19 vaccine developed by Pfizer and the                                                                        German pharmaceutical company BioNTech.

    The vaccine made history not only because it reported a 95 percent efficacy rate                                                                        at preventing COVID-19 in clinical trials, but because it is the first vaccine                                                                    ever approved by the FDA for human use that is based on RNA technology.

    “The development of RNA vaccines is a great boon to the future of treating                                                                   infectious diseases,” says Lynne Maquat, the J. Lowell Orbison Distinguished                                                          Service Alumni Professor in biochemistry and biophysics, oncology, and                                                                pediatrics at Rochester and the director of Rochester’s Center for RNA Biology.

    COVID-19, short for “coronavirus disease 2019,” is caused by the novel                                                              coronavirus SARS-CoV-2. Like many other viruses, SARS-CoV-2 is an RNA virus.                                                               This means that, unlike in humans and other mammals, the genetic material for                                                           SARS-CoV-2 is encoded in ribonucleic acid (RNA).                                                                                                        The viral RNA is sneaky: its features cause the protein synthesis machinery in                                                         humans to mistake it for RNA produced by our own DNA.

    For that reason, several of the leading COVID-19 vaccines and treatments                                                                                      are based on RNA technology.

    A contingent of researchers at the University of Rochester study the RNA of                                                           viruses to better understand how RNAs work and how they are involved in                                                               diseases. This RNA research provides an important foundation for developing                                                         vaccines and other drugs and therapeutics to disrupt the virus and stop infections.

    “Understanding RNA structure and function helps us understand how to throw a                                                              therapeutic wrench into what the COVID-19 RNA does—make new virus that can                                                             infect more of our cells and also the cells of other human beings,” Maquat says.


    In the past few decades, as scientists came to realize that genetic material is largely regulated by the RNA it encodes, that most of our DNA produces RNA,       and that RNA is not only a target but also a tool for disease therapies, “the RNA research world has exploded,” Maquat says. “The University of Rochester                                                        understood this.”

    In 2007, Maquat founded The Center for RNA Biology as a means of                                                                 conducting interdisciplinary research in the function, structure, and processing                                                                  of RNAs. The Center involves researchers from both the River Campus and the                                                                     Medical Center, combining expertise in biology, chemistry, engineering, neurology,                                                       and pharmacology.

    “Our strength as a university is our diversity of research expertise, combined                                                                 with our highly collaborative nature,” says Dragony Fu, an associate professor                                                                of biology on the River Campus and a member of the Center for RNA Biology.                                                             “We are surrounded by outstanding researchers who enhance our understanding                                                           of RNA biology, and a medical center that provides a translational aspect where                                                                        the knowledge gained from RNA biology can be applied for therapeutics.”

    How does RNA relate to disease?

    graphic created by the New York Times illustrates how the coronavirus that                                                            causes COVID-19 enters the body through the nose, mouth, or eyes and attaches                                                                        to our cells. Once the virus is inside our cells, it releases its RNA.                                                                                Our hijacked cells serve as virus factories, reading the virus’s RNA and making                                                                     long viral proteins to compromise the immune system.                                                                                                        The virus assembles new copies of itself and spreads to more parts of the body                                                                   and—by way of saliva, sweat, and other bodily fluids—to other humans.

    “Once the virus is in our cells, the entire process of infection and re-infection                                                          depends on the viral RNA,” Maquat says.

    One of the reasons viruses are such a challenge is that they change and                                                                  mutate in response to drugs.

    That means novel virus treatments and vaccines have to be created each time                                                                a new strain of virus presents itself. Armed with innovative research on the                                                                        fundamentals of RNA, scientists are better able to develop and test therapeutics                                                                  that directly target the RNAs and processes critical to a virus’s life cycle.

    How do RNA vaccines work?

    Traditional vaccines against viruses like influenza inject inactivated virus proteins                                                                                  called antigens. The antigens stimulate the body’s immune system to recognize                                                                      the specific virus and produce antibodies in response, with the hope                                                                                   that these antibodies will fight against future virus infection.

    RNA-based vaccines—such as those developed by Pfizer/BioNTech and American                                               biotechnology company Moderna—do not introduce an antigen, but instead                                                                                          inject a short sequence of synthetic messenger RNA (mRNA) that is enclosed in a                                                    specially engineered lipid nanoparticle.                                                                                                                          This mRNA provides cells with instructions to produce the virus antigen                                                                themselves.

    Once the mRNA from a vaccine is in our body, for example,                                                                                               it “instructs” the protein synthesis machinery in our cells, which normally                                                                           generates proteins from the mRNAs that derive from our genes, to produce                                                                        a piece of the SARS-CoV-2 virus spike protein.                                                                                                               Since the SARS-CoV-2 virus spike protein is foreign to our bodies,                                                                                   our bodies will then make antibodies that inactivate the protein.

    “Should the virus enter our body from an infected person,                                                                                              these antibodies will bind to and inactivate the virus by binding to its                                                                                spike proteins, which coat the outside of the viral capsule,” Maquat says.

    An RNA-based vaccine therefore acts as a code to instruct our human cells to                                                                                            make many copies of the virus protein which, as a consequence, creates                                                           antibodies resulting in an immune response.

    Unlike more traditional vaccines, RNA-based vaccines are also beneficial in                                                                      that they eliminate the need to work with the actual virus.

    “Working with a live virus is costly and very involved, requiring that researchers                                                              use special biosafety laboratories and wear bulky personal protective                                                                         equipment so that the virus is ‘biocontained,’ and no one gets infected,”                                                                         Maquat says.

    Developing a vaccine from a live virus additionally takes much longer than                                                                     generating an mRNA-based vaccine, but “no one should think the process is                                                                simple,”  Maquat says of the Pfizer/BioNTech vaccine.                                                                                                 “Since it is the first of its kind, a lot had to be worked out.”

    What does RNA stand for?

    RNA stands for ribonucleic acid.

    What is RNA?

    RNA delivers the genetic instructions contained in DNA to the rest of the cell.

    What does Covid stand for?

    Covid-19 stands for “coronavirus disease 2019.”

    How is Rochester’s RNA research applicable to COVID-19? 

    Horizontal portraits of Doug Anderson, Dragony Fu, and Lynne Maquat, scientists who study RNA of viruses.






    Researchers Douglas Anderson, Dragony Fu, and Lynne Maquat are among the scientists at the University of Rochester                                                                                                                who study the RNA of viruses to better understand how RNAs work and how they are involved in diseases.                                                                                                              (University of Rochester photos / Matt Wittmeyer / J. Adam Fenster)                                                                                                                                                                                               

    Maquat has been studying RNA since 1972 and was part of the earliest wave of                                                     scientists to realize the important role RNA plays in human health and disease.

    Our cells have a number of ways to combat viruses in what can be viewed as                                                                 an “arms race” between host and virus.                                                                                                                            One of the weapons in our cells’ arsenal is an RNA surveillance mechanism                                                                     Maquat discovered called nonsense-mediated mRNA decay (NMD).

    “Nonsense-mediated mRNA decay protects us from many genetic mutations that                                                           could cause disease if NMD were not active to destroy the RNA harbouring the                                                                mutation,” she says.

    Maquat’s discovery has contributed to the development of drug therapies for                                                                 genetic disorders such as cystic fibrosis, and may be useful in developing                                                                        treatments for coronavirus.

    “NMD also helps us combat viral infections, which is why many viruses either                                                               inhibit or evade NMD,” she adds. “The genome of the virus COVID-19 is                                                                           a positive-sense, single-stranded RNA. It is well known that other positive-sense,                                                          single-stranded RNA viruses evade NMD by having RNA structures that prevent                                                             NMD from degrading viral RNAs.”

    Maquat’s lab has been collaborating with a lab at Harvard University to test how                                                                 viral proteins can inhibit the NMD machinery.

    Their recent work is focused on the SARS-CoV-2 structural protein called N. Lab                                                   experiments and data sets from infected human cells indicate this virus is                                                                 unusual because it does not inhibit the NMD pathway that regulates many of our                                                          genes and some of the virus’s genes. Instead, the virus N protein seems to                                                              promote the pathway.

    “SARS-CoV-2 reproduces its RNA genome with much higher efficiency than                                                                               other pathogenic human viruses,” Maquat says. “Maybe there is a connection                                                            there; time will tell.”

    In the Department of Biology, Fu and Jack Werren, the Nathaniel and                                                                                Helen Wisch Professor of Biology, received expedited funding awards from the                                                            National Science Foundation to apply their expertise in cellular and evolutionary                                                         biology to research proteins involved in infections from COVID-19.                                                                                  The funding was part of the NSF’s Rapid Response Research (RAPID) program                                                               to mobilize funding for high priority projects.

    Werren’s research will be important in ameliorating some of the potential side                                                               effects of COVID-19 infections, including blood clots and heart diseases,                                                                                           while Fu’s research will provide insight into the potential effects of viral infection                                                             on human cell metabolism.

    “Our research will provide insight into the potential effects of viral infection on                                                                         host cellular processes,” Fu says. “Identifying which cell functions are affected                                                                 by the virus could help lessen some of the negative effects caused by COVID-19.”                                                                  

    Douglas Anderson, an assistant professor of medicine in the                                                                                                Aab Cardiovascular Research Institute and a member of the Center for                                                                         RNA Biology, studies how RNA mutations can give rise to human disease                                                                      and has found that alternative therapeutics, such as the gene-editing                                                                 technology CRISPR, may additionally “usher in a new approach to how we                                                                target and combat infectious diseases,” he says.

    For the past few years, Anderson’s lab has developed tools and delivery systems                                                                          that use the RNA-targeting CRISPR-Cas13 to treat human genetic diseases that                                                         affect muscle function. CRISPR-Cas13 is like a molecular pair of scissors that                                                               can target specific RNAs for degradation, using small, programmable guide RNAs.

    When the health crisis first became apparent in Wuhan, China, researchers in                                                          Anderson’s lab turned their focus toward developing a                                                                                                       CRISPR-Cas13 therapeutic aimed at SARS-CoV-2.                                                                                                                   Applying the knowledge already available about coronavirus RNA replication,                                                                 they designed single CRISPR guide RNAs capable of targeting every                                                                                  viral RNA that is made within a SARS-CoV-2 infected cell. Using a novel                                                                                cloning method developed in Anderson’s lab, multiple CRISPR guide-RNAs                                                                    could be packaged into a single therapeutic vector (a genetically engineered                                                                                    carrier) to target numerous viral RNA sites simultaneously.                                                                                              The multi-pronged targeting strategy could be used as a therapy to                                                                          safeguard against virus-induced cell toxicity and prevent ‘escape’ of viruses                                                                  which may have undergone mutation.

    “Infectious viruses and pandemics seemingly come out of nowhere,                                                                             which has made it hard to rapidly develop and screen traditional small molecule                                                       therapeutics or vaccines,” Anderson says.                                                                                                                               “There is a clear need to develop alternative targeted therapeutics,                                                                                                        such as CRISPR-Cas13, which have the ability to be rapidly reprogrammed                                                                         to target new emerging pandemics.”

    bat with wings spread.                    While many new treatments for the novel coronavirus are being considered,                                                                  there is one thing that is certain, Maquat says: “Targeting RNA,                                                                                                  or the proteins it produces, is essential for therapeutically combatting this disease.”

    What role will RNA play in the future of vaccines                                                                          and disease treatments?

    Most people living in the United States today have only read about the                                                                           1918 flu pandemic and the relatively recent RNA viruses,                                                                                                such as Ebola or Zika, that are seen largely in other countries.

    “RNA treatments will most likely be a wave of the future for these and other                                                                            emerging diseases,” Maquat says. “Epidemiologists know new infectious                                                                  pathogens are coming given how small the world has become with international                                                           travel, including to and from places where humans and animals are in close                                                             contact.”

    Bats, in particular, are reservoirs for viruses.                                                                                                            Many bat species are able to live with viruses without experiencing ill effects,                                                                       given the bats’ unusual physiology.                                                                                                                                          If these bat viruses mutate so they become capable of infecting humans,                                                                         however, there will be new diseases, Maquat says.

    “It is just a matter of when this will happen and what the virus will be.                                                                               The hope is that we will be ready and able to develop vaccines against these                                                                     new viruses with the new pipelines that have been put in place for COVID-19.”

    This story was originally published on April 28, 2020, and updated on                                                                       December 14, 2020.


    Read more

    health care worker gives someone a vaccineFDA votes to approve emergency use of Pfizer coronavirus vaccine
    Researchers and volunteers in Rochester have been involved in the testing of the Pfizer/BioNTech vaccine since May, and technologies used in the development of the vaccine can trace their origins to decades of infectious disease research conducted at Rochester.

    Bats offer clues to treating COVID-19
    Bats carry many viruses, including the one behind COVID-19, without becoming ill. University of Rochester biologists are studying the immune system of bats to find potential ways to “mimic” that system in humans.
    illustration of cellular enzymeRochester biologists selected for ‘rapid research’ on COVID-19
    Rochester biologists are exploring how coronavirus interacts with cellular proteins to cause COVID-19 under a priority NSF program.

     

    Tags: ,                                                                        ,                                                                                                   ,                                                                                   

    CategoryScience & Technology

    Stephanie Hulse, Greenpeace Canada <stephanie.hulse@greenpeace.ca>

    Nelson,   A few months ago, I told you about the City of Montréal’s plans to ban natural gas in new buildings in the Fall of 2024. And I hav...